FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?

J Clin Oncol. 2019 Jul 1;37(19):1604-1607. doi: 10.1200/JCO.19.00321. Epub 2019 Apr 29.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Ethics, Medical*
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Mutation
  • Neoplasm Recurrence, Local
  • Prognosis
  • Randomized Controlled Trials as Topic / ethics*
  • Research Design
  • Transplantation, Homologous
  • Treatment Outcome
  • fms-Like Tyrosine Kinase 3 / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3